Mazdutide vs Survodutide: prices, identity and regulatory status (2026)
Mazdutide and Survodutide are different research compounds, not substitutes for each other: Mazdutide is a single compound (C207H317N45O65); Survodutide is a single compound (C192H289N47O61). Neither product has a current in-stock price right now. Mazdutide has no Drugs@FDA application; Survodutide has no Drugs@FDA application.
Mazdutide vs Survodutide: current prices and packages
| Compared property | Mazdutide | Survodutide |
|---|---|---|
| Category | GLP-1 | GLP-1 |
| Compared package | 10mg · Vial | 10mg · Vial |
| Lowest current price | No current in-stock price | No current in-stock price |
| Price per labelled mg | — | — |
| Package sizes | 5mg, 10mg | 5mg, 6mg, 10mg |
| Vendors with current prices | 0 (1 tracked) | 0 (1 tracked) |
| Form at this package | Vial | Vial |
| Stock | Out of stock | Out of stock |
Prices exclude shipping. The price per labelled mg is always given per mg, so different package sizes compare directly; it is shown only for single-compound vials and powders with a labelled mass. Blends, capsules, liquids and IU-labelled packages are compared by package total.
Identity, regulatory status and registered research
| Compared property | Mazdutide | Survodutide |
|---|---|---|
| Molecular formula | C207H317N45O65 | C192H289N47O61 |
| Molecular weight | 4476 g/mol | 4232 g/mol |
| Sequence | — | — |
| CAS Registry Number | — | — |
| Registered clinical trials | 40 (24 active) · Phase 4: 5, Phase 3: 11, Phase 2: 12 | 27 (9 active) · Phase 3: 11, Phase 2: 3, Phase 1: 13 |
| Human intervention studies | 6 | 6 |
| US regulatory status | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search |
Identity data: PubChem, FDA GSRS and EPA records; registry counts: ClinicalTrials.gov; status: Drugs@FDA. A matching name does not verify the contents of a supplier's lot.
Key human studies
Mazdutide
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature, 2026
- Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature, 2026
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA, 2026
Survodutide
- Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine, 2026
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine, 2026
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England journal of medicine, 2024
Studies are listed as records, newest first; they are not evidence that a research product is safe or effective.
Where to buy each compound
Mazdutide
Mazdutide is a catalogue entry whose compound-specific reference review has not yet been completed.
No vendor has a current in-stock price for this package.
Mazdutide prices →Price history →Survodutide
Survodutide is a catalogue entry whose compound-specific reference review has not yet been completed.
No vendor has a current in-stock price for this package.
Survodutide prices →Price history →Related comparisons
Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price only. PeptideTech earns a commission when you buy through a link; it never changes the order.
Full method →